Overview Dividends

(ETON) Eton Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29772L1089

Rare Disease Treatments, Pharmaceuticals, Medications

ETON EPS (Earnings per Share)

EPS (Earnings per Share) of ETON over the last years for every Quarter: "2020-09-30": -0.31, "2020-12-31": -0.32, "2021-03-31": 0.19, "2021-06-30": -0.1, "2021-09-30": -0.24, "2021-12-31": 0.04, "2022-03-31": -0.21, "2022-06-30": -0.06, "2022-09-30": -0.12, "2022-12-31": 0.04, "2023-03-31": -0.1, "2023-06-30": 0.15, "2023-09-30": -0.02, "2023-12-31": -0.09, "2024-03-31": -0.03, "2024-06-30": -0.12, "2024-09-30": 0.02, "2024-12-31": -0.02, "2025-03-31": -0.06, "2025-06-30": 0.03,
EPS Growth (3Y CAGR): 93899.19%
EPS Trend (3Y Correlation): 6.7%

ETON Revenue

Revenue of ETON over the last years for every Quarter: 2020-09-30: -0.161, 2020-12-31: 0.081, 2021-03-31: 11.897, 2021-06-30: 3.067, 2021-09-30: 0.775, 2021-12-31: 6.093, 2022-03-31: 2.176, 2022-06-30: 7.358, 2022-09-30: 3.219, 2022-12-31: 8.498, 2023-03-31: 5.304, 2023-06-30: 11.997, 2023-09-30: 7.028, 2023-12-31: 7.313, 2024-03-31: 7.966, 2024-06-30: 9.074, 2024-09-30: 10.324, 2024-12-31: 11.647, 2025-03-31: 17.282, 2025-06-30: 18.928,
Revenue Growth (3Y CAGR): 90.45%
Revenue Trend (3Y Correlation): 81.6%

Description: ETON Eton Pharmaceuticals

Eton Pharmaceuticals Inc (NASDAQ:ETON) is a pharmaceutical company specializing in rare disease treatments, with a portfolio of commercial products and late-stage development candidates. The companys commercial products include Increlex, Alkindi Sprinkle, Galzin, PKU Golike, Carglumic Acid, Betaine Anhydrous, and Nitisinone, targeting various rare conditions such as primary IGF-1 deficiency, adrenal insufficiency, and Wilson disease.

From a business perspective, Eton Pharmaceuticals has a relatively small market capitalization of $363.91M, indicating a potentially high-risk, high-reward investment opportunity. The companys forward P/E ratio of 45.25 suggests that investors are expecting significant growth, but the negative Return on Equity (RoE) of -23.41% raises concerns about the companys current profitability.

To further evaluate Eton Pharmaceuticals performance, key performance indicators (KPIs) such as revenue growth, R&D expenses as a percentage of revenue, and cash burn rate should be monitored. For instance, a high R&D expense ratio could indicate a strong commitment to innovation, but also potentially unsustainable spending. Additionally, the companys cash position and burn rate will be crucial in determining its ability to fund future development and commercialization efforts.

From a product development perspective, Eton Pharmaceuticals has a promising pipeline, with several late-stage candidates, including ET-400, ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector, targeting various rare conditions. The success of these candidates will be critical in driving future revenue growth and improving the companys financial performance.

ETON Stock Overview

Market Cap in USD 468m
Sub-Industry Pharmaceuticals
IPO / Inception 2018-11-13

ETON Stock Ratings

Growth Rating 75.9%
Fundamental 42.7%
Dividend Rating -
Return 12m vs S&P 500 169%
Analyst Rating 4.67 of 5

ETON Dividends

Currently no dividends paid

ETON Growth Ratios

Growth Correlation 3m 90.2%
Growth Correlation 12m 74.3%
Growth Correlation 5y 18.1%
CAGR 5y 105.65%
CAGR/Max DD 3y 2.31
CAGR/Mean DD 3y 6.88
Sharpe Ratio 12m 1.52
Alpha 0.08
Beta 0.919
Volatility 48.10%
Current Volume 292.2k
Average Volume 20d 217.2k
Stop Loss 16.6 (-5.5%)
Signal -0.47

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (-4.13m TTM) > 0 and > 6% of Revenue (6% = 3.49m TTM)
FCFTA 0.06 (>2.0%) and ΔFCFTA -13.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 51.30% (prev 23.00%; Δ 28.30pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.12 (>3.0%) and CFO 12.2m > Net Income -4.13m (YES >=105%, WARN >=100%)
Net Debt (-22.1m) to EBITDA (1.49m) ratio: -14.80 <= 3.0 (WARN <= 3.5)
Current Ratio 1.77 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (26.9m) change vs 12m ago 4.33% (target <= -2.0% for YES)
Gross Margin 59.41% (prev 59.48%; Δ -0.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 87.16% (prev 98.61%; Δ -11.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -0.04 (EBITDA TTM 1.49m / Interest Expense TTM 3.70m) >= 6 (WARN >= 3)

Altman Z'' -3.20

(A) 0.29 = (Total Current Assets 68.4m - Total Current Liabilities 38.6m) / Total Assets 101.7m
(B) -1.10 = Retained Earnings (Balance) -112.0m / Total Assets 101.7m
warn (B) unusual magnitude: -1.10 — check mapping/units
(C) -0.00 = EBIT TTM -152.0k / Avg Total Assets 66.7m
(D) -1.44 = Book Value of Equity -112.0m / Total Liabilities 77.7m
Total Rating: -3.20 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 42.72

1. Piotroski 3.0pt = -2.0
2. FCF Yield 1.26% = 0.63
3. FCF Margin 10.26% = 2.57
4. Debt/Equity 1.26 = 1.76
5. Debt/Ebitda 20.21 = -2.50
6. ROIC - WACC -9.35% = -11.69
7. RoE -18.59% = -2.50
8. Rev. Trend 81.57% = 6.12
9. EPS Trend 6.69% = 0.33

What is the price of ETON shares?

As of September 17, 2025, the stock is trading at USD 17.56 with a total of 292,156 shares traded.
Over the past week, the price has changed by -1.62%, over one month by +7.27%, over three months by +23.92% and over the past year by +219.27%.

Is Eton Pharmaceuticals a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Eton Pharmaceuticals (NASDAQ:ETON) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 42.72 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ETON is around 17.97 USD . This means that ETON is currently overvalued and has a potential downside of 2.33%.

Is ETON a buy, sell or hold?

Eton Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ETON.
  • Strong Buy: 2
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ETON price?

Issuer Target Up/Down from current
Wallstreet Target Price 30 70.8%
Analysts Target Price 30 70.8%
ValueRay Target Price 20.1 14.6%

Last update: 2025-09-05 04:41

ETON Fundamental Data Overview

Market Cap USD = 468.0m (468.0m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 25.4m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 11.6959
P/S = 8.0433
P/B = 19.2393
Beta = 1.135
Revenue TTM = 58.2m USD
EBIT TTM = -152.0k USD
EBITDA TTM = 1.49m USD
Long Term Debt = 27.4m USD (from longTermDebt, last quarter)
Short Term Debt = 2.79m USD (from shortTermDebt, last quarter)
Debt = 30.2m USD (Calculated: Short Term 2.79m + Long Term 27.4m)
Net Debt = -22.1m USD (from netDebt column, last quarter)
Enterprise Value = 472.8m USD (468.0m + Debt 30.2m - CCE 25.4m)
Interest Coverage Ratio = -0.04 (Ebit TTM -152.0k / Interest Expense TTM 3.70m)
FCF Yield = 1.26% (FCF TTM 5.97m / Enterprise Value 472.8m)
FCF Margin = 10.26% (FCF TTM 5.97m / Revenue TTM 58.2m)
Net Margin = -7.10% (Net Income TTM -4.13m / Revenue TTM 58.2m)
Gross Margin = 59.41% ((Revenue TTM 58.2m - Cost of Revenue TTM 23.6m) / Revenue TTM)
Tobins Q-Ratio = -4.22 (set to none) (Enterprise Value 472.8m / Book Value Of Equity -112.0m)
Interest Expense / Debt = 3.97% (Interest Expense 1.20m / Debt 30.2m)
Taxrate = 21.0% (US default)
NOPAT = -152.0k (EBIT -152.0k, no tax applied on loss)
Current Ratio = 1.77 (Total Current Assets 68.4m / Total Current Liabilities 38.6m)
Debt / Equity = 1.26 (Debt 30.2m / last Quarter total Stockholder Equity 24.0m)
Debt / EBITDA = 20.21 (Net Debt -22.1m / EBITDA 1.49m)
Debt / FCF = 5.06 (Debt 30.2m / FCF TTM 5.97m)
Total Stockholder Equity = 22.2m (last 4 quarters mean)
RoA = -4.06% (Net Income -4.13m, Total Assets 101.7m )
RoE = -18.59% (Net Income TTM -4.13m / Total Stockholder Equity 22.2m)
RoCE = -0.31% (Ebit -152.0k / (Equity 22.2m + L.T.Debt 27.4m))
RoIC = -0.33% (NOPAT -152.0k / Invested Capital 45.7m)
WACC = 9.02% (E(468.0m)/V(498.2m) * Re(9.40%)) + (D(30.2m)/V(498.2m) * Rd(3.97%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 81.82 | Cagr: 0.53%
Discount Rate = 9.40% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 64.57% ; FCFE base≈6.00m ; Y1≈3.94m ; Y5≈1.80m
Fair Price DCF = 1.07 (DCF Value 28.6m / Shares Outstanding 26.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 6.69 | EPS CAGR: 93.9k% | SUE: 0.21 | # QB: False
Revenue Correlation: 81.57 | Revenue CAGR: 90.45%

Additional Sources for ETON Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle